文献速递肝病

贝特类联合奥贝胆酸可正常化难治性原发性胆汁性胆管炎生化指标

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
PubMed 文献 · Aliment Pharmacol Ther · 2021-03-25

这项多中心回顾性队列研究纳入58例UDCA应答不足的难治性PBC患者,比较UDCA+OCA+贝特类三联与二线单药治疗的生化改善。三联治疗与ALP降低22%/年(95%CI 12%-31%)、ALP正常化OR 3.4(95%CI 1.4-8.2)及Paris-2和Toronto标准达标OR 6.8和9.2相关,OCA-Fibrate顺序组瘙痒改善。

要点

  • 三联治疗较二线单药显著降低ALP,年均降幅22%(95%CI 12%-31%)
  • 三联治疗ALP正常化OR 3.4,Paris-2和Toronto达标OR 6.8和9.2
  • OCA-Fibrate顺序组瘙痒显著改善,Fibrate-OCA组无此改善

核心结论

  • UDCA、OCA与贝特类三联治疗可使难治性PBC患者生化肝脏指标正常化并改善瘙痒。

研究设计与样本

  • 多中心、非对照回顾性队列研究,纳入58例接受UDCA≥3个月且因二线治疗失败加用OCA和贝特类(苯扎贝特或非诺贝特)≥3个月的PBC患者。
  • 按二线药物顺序分为OCA-Fibrate组(OCA二线、贝特类三线)和Fibrate-OCA组(贝特类二线、OCA三线),各占一半。
  • 采用广义线性混合效应模型分析生化肝脏指标和瘙痒变化。

主要发现

  • 三联治疗平均持续11个月(范围3-26个月)。
  • 与二线单药治疗相比,三联治疗第一年ALP降低22%(95%CI 12%-31%),OCA-Fibrate组效应强于Fibrate-OCA组。
  • 三联治疗与ALP正常化OR 3.4(95%CI 1.4-8.2)相关,并显著降低GGT、ALT、AST和总胆红素。
  • 达到Paris-2和Toronto生化应答标准的OR分别为6.8(95%CI 2.8-16.7)和9.2(95%CI 3.4-25.1)。
  • 三联治疗在OCA-Fibrate组显著改善瘙痒,在Fibrate-OCA组未改善。

关键数值与推荐

  • ALP降低22%/第一年(95%CI 12%-31%)。
  • ALP正常化OR 3.4(95%CI 1.4-8.2)。
  • Paris-2标准达标OR 6.8(95%CI 2.8-16.7),Toronto标准达标OR 9.2(95%CI 3.4-25.1)。

临床怎么用

  • 对UDCA应答不足且二线单药治疗失败的难治性PBC患者,可考虑UDCA+OCA+贝特类三联治疗以改善生化指标。
  • OCA-Fibrate顺序可能较Fibrate-OCA顺序更有利于ALP降低和瘙痒改善,但需个体化评估。

局限性

  • 非对照回顾性研究,样本量58例,可能存在选择偏倚和混杂。
  • 平均治疗时间11个月(范围3-26个月),长期安全性和疗效未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obeticholic acid (OCA) and fibrates are second-line therapies for patients with primary biliary cholangitis (PBC) with an inadequate response to ursodeoxycholic acid (UDCA). AIM: To know whether OCA and fibrates, administered together in combination with UDCA, have additive beneficial effects in patients with difficult-to-treat PBC. METHODS: PBC patients treated for ≥3 months with UDCA, OCA and fibrates (bezafibrate or fenofibrate) due to failure of either second-line therapy were included in a multicentre, uncontrolled retrospective cohort study. Changes in biochemical liver tests and pruritus were analysed using a generalised linear mixed-effect model. RESULTS: Among 58 patients included, half received OCA as second-line and fibrates as third-line therapy (Group OCA-Fibrate), while the other half had the inverse therapeutic sequence (Group Fibrate-OCA). The mean duration of triple therapy was 11 months (range 3-26). Compared to dual therapy, triple therapy was associated with a significant gain in alkaline phosphatase (ALP) reduction: 22% per first year (95% CI 12%-31%), an effect that was stronger in OCA-Fibrate than in Fibrate-OCA group. Triple therapy was associated with a 3.4 (95% CI 1.4-8.2) odds ratio (OR) of reaching normal ALP and with a significant decrease in gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin. The ORs of achieving the Paris-2 and Toronto criteria of adequate biochemical response were 6.8 (95% CI 2.8-16.7) and 9.2 (95% CI 3.4-25.1) respectively. Finally, triple therapy significantly improved pruritus in OCA-Fibrate but not in Fibrate-OCA group. CONCLUSIONS: Triple therapy with UDCA, OCA and fibrates is able to normalise biochemical liver tests and improve pruritus in patients with difficult-to-treat PBC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Soret PA, Lam L, Carrat F, et al. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. Aliment Pharmacol Ther. 2021. PMID: 33764590. doi:10.1111/apt.16336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。